Quick Answer
Theriva Biologics, Inc. reported Operating Income Loss of -$24.05 million for the year ending 2025.
- Theriva Biologics, Inc. showed an increase of +8.7% in Operating Income Loss from 2024 to 2025.
- This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $973.3 thousand | Q3 2010: -$733.1 thousand | Q2 2011: -$919.5 thousand | Q3 2011: -$938.2 thousand | Q3 2013: -$3.37 million | Q1 2014: -$3.84 million | Q2 2014: -$4.65 million | Q3 2014: -$4.91 million | Q1 2015: -$8.21 million | Q2 2015: -$9.73 million | Q3 2015: -$11.65 million | Q1 2016: -$10.58 million | Q2 2016: -$9.31 million | Q3 2016: -$9.16 million | Q1 2017: -$8.15 million | Q2 2017: -$6.48 million | Q3 2017: -$5.84 million | Q1 2018: -$4.99 million | Q2 2018: -$5.00 million | Q3 2018: -$4.32 million | Q1 2019: -$3.57 million | Q2 2019: -$3.64 million | Q3 2019: -$5.24 million | Q1 2020: -$3.03 million | Q2 2020: -$2.89 million | Q3 2020: -$2.11 million | Q1 2021: -$2.54 million | Q2 2021: -$3.20 million | Q3 2021: -$3.28 million | Q1 2022: -$4.25 million | Q2 2022: -$5.03 million | Q3 2022: -$4.99 million | Q1 2023: -$5.18 million | Q2 2023: -$5.82 million | Q3 2023: -$4.22 million | Q1 2024: -$5.39 million | Q2 2024: -$8.49 million | Q3 2024: -$7.89 million | Q1 2025: -$4.42 million | Q2 2025: -$13.13 million | Q3 2025: -$4.44 million.
- Over the full 14 years of available data (2012 to 2025), Theriva Biologics, Inc.'s Operating Income Loss has declined by 39.0%.
- Historical annual values: Fiscal year 2025: -$24.05 million | Fiscal year 2024: -$26.35 million | Fiscal year 2023: -$21.43 million | Fiscal year 2022: -$21.58 million | Fiscal year 2021: -$14.27 million | Fiscal year 2020: -$10.16 million | Fiscal year 2019: -$15.66 million | Fiscal year 2018: -$17.57 million | Fiscal year 2017: -$26.25 million | Fiscal year 2016: -$39.25 million | Fiscal year 2015: -$40.98 million | Fiscal year 2014: -$20.50 million | Fiscal year 2013: -$12.34 million | Fiscal year 2012: -$17.30 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: